Roche Holding AG (XSWX:ROG) Stock News, Headlines & Updates
Roche Holding AG Stock News from GuruFocus
- 1
- 2
Jul 21, 2025
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease | RHHBY Stock News
GuruFocus News • 12:15am
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease | RHHBY Stock News
GuruFocus News • 12:15am
Jul 18, 2025
Genentech's Columvi Expansion Bid Rejected by FDA (RHHBY)
GuruFocus News • 2:59pm
Genentech Provides Update on Supplemental Biologics License Application for Columvi Combination for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | RHHBY Stock News
GuruFocus News • 11:00am
Jun 30, 2025
Changes to the Roche Enlarged Corporate Executive Committee | RHHBY Stock News
GuruFocus News • 12:15am
Jun 23, 2025
Early data suggest Roche's NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A | RHHBY Stock News
GuruFocus News • 12:15am
Jun 20, 2025
Roche (RHHBY) Study Shows Lunsumio and Polivy Effectiveness in Lymphoma Treatment
GuruFocus News • 1:58pm
Roche's Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma | RHHBY Stock News
GuruFocus News • 11:00am
Genentech's Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma | RHHBY Stock News
GuruFocus News • 11:00am
Jun 16, 2025
Genentech Provides Update on Phase III Verona Study | RHHBY Stock News
GuruFocus News • 10:45am
Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease | RHHBY Stock News
GuruFocus News • 12:30am
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease | RHHBY Stock News
GuruFocus News • 12:16am
Jun 15, 2025
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidysâ„¢ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients | RHHBY Stock News
GuruFocus News • 12:15am
Jun 04, 2025
Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA) | RHHBY Stock News
GuruFocus News • 12:15am
Jun 03, 2025
Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer | RHHBY Stock News
GuruFocus News • 12:15am
Jun 02, 2025
Genentech's Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer | RHHBY Stock News
GuruFocus News • 3:16pm
May 31, 2025
New data show Roche's Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer | RHHBY Stock News
GuruFocus News • 7:15am
New Data Show Genentech's Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer | RHHBY Stock News
GuruFocus News • 7:15am
May 30, 2025
Roche's fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis | RHHBY Stock News
GuruFocus News • 12:15am
May 23, 2025
Roche (RHHBY) Gains EMA Panel Support for Itovebi in Breast Cancer
GuruFocus News • 10:56am
CHMP recommends EU approval of Roche's Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer | RHHBY Stock News
GuruFocus News • 8:16am
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology | RHHBY Stock News
GuruFocus News • 12:30am
New two-year follow-up of Roche's Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients | RHHBY Stock News
GuruFocus News • 12:15am
New Two-year Follow-up of Genentech's Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients | RHHBY Stock News
GuruFocus News • 12:15am
May 22, 2025
Roche (RHHBY) Gains FDA Approval for Susvimo in Diabetic Retinopathy
GuruFocus News • 2:56pm
FDA approves Roche's Susvimo for diabetic retinopathy | RHHBY Stock News
GuruFocus News • 11:00am
FDA Approves Genentech's Susvimo for Diabetic Retinopathy | RHHBY Stock News
GuruFocus News • 11:00am
May 20, 2025
Roche (RHHBY) Faces Setback as FDA Panel Rejects Columvi for Lymphoma Use
GuruFocus News • 3:55pm
Roche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma | RHHBY Stock News
GuruFocus News • 2:00pm
May 14, 2025
Roche (RHHBY) Warns Executive Order May Impact U.S. Investments
GuruFocus News • 10:58am
May 13, 2025
Ten-year APHINITY data show Roche's Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer | RHHBY Stock News
GuruFocus News • 12:15am
Ten-Year APHINITY Data Show Genentech's Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer | RHHBY Stock News
GuruFocus News • 12:15am
May 12, 2025
Roche (RHHBY) Invests $700M in North Carolina Drug Facility
GuruFocus News • 10:55am
Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub
PRNewswire • 10:00am
Roche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub | RHHBY Stock News
GuruFocus News • 9:45am
Roche and Genentech Announce New North Carolina Manufacturing Facility | RHHBY Stock News
GuruFocus News • 7:50am
May 06, 2025
Roche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity | RHHBY Stock News
GuruFocus News • 12:15am
Apr 30, 2025
CHMP recommends EU label update for Roche's Phesgo to allow administration outside of clinical settings | RHHBY Stock News
GuruFocus News • 12:15am
Apr 29, 2025
Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer | RHHBY Stock News
GuruFocus News • 12:15am
Apr 25, 2025
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news